Published in J Pharmacogenomics Pharmacoproteomics on March 01, 2014
Immune cell-based screening assay for response to anticancer agents: applications in pharmacogenomics. Pharmgenomics Pers Med (2015) 0.82
Quantitative high-throughput screening data analysis: challenges and recent advances. Drug Discov Today (2014) 0.82
Lymphoblastoid cell lines models of drug response: successes and lessons from this pharmacogenomic model. Curr Mol Med (2014) 0.77
Estimating Potency in High-Throughput Screening Experiments by Maximizing the Rate of Change in Weighted Shannon Entropy. Sci Rep (2016) 0.75
Identifying genes that mediate anthracyline toxicity in immune cells. Front Pharmacol (2015) 0.75
An Introduction to Terminology and Methodology of Chemical Synergy-Perspectives from Across Disciplines. Front Pharmacol (2017) 0.75
A data-driven weighting scheme for multivariate phenotypic endpoints recapitulates zebrafish developmental cascades. Toxicol Appl Pharmacol (2016) 0.75
An investigation of gene-gene interactions in dose-response studies with Bayesian nonparametrics. BioData Min (2015) 0.75
Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci U S A (2004) 2.37
Pharmacogenomic discovery using cell-based models. Pharmacol Rev (2009) 1.96
Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res (2007) 1.73
Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther (2008) 1.67
Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics (2012) 1.63
Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. Pharmacogenomics (2011) 1.34
The quantitative analysis of drug-receptor interactions: a short history. Trends Pharmacol Sci (2006) 1.26
A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT. Pharmacogenet Genomics (2012) 1.23
Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines. Pharmacogenomics (2014) 1.00
Identification and replication of loci involved in camptothecin-induced cytotoxicity using CEPH pedigrees. PLoS One (2011) 1.00
Genomic profiling in CEPH cell lines distinguishes between the camptothecins and indenoisoquinolines. Mol Cancer Ther (2011) 0.98
Multivariate methods and software for association mapping in dose-response genome-wide association studies. BioData Min (2012) 0.96
A comparison of association methods for cytotoxicity mapping in pharmacogenomics. Front Genet (2011) 0.96
How desirable are your IC50s? A way to enhance screening-based decision making. J Biomol Screen (2010) 0.89
Optimization of nonlinear dose- and concentration-response models utilizing evolutionary computation. Dose Response (2010) 0.86
Analysis of Hill interaction coefficients and the invalidity of the Kwon and Brown equation. J Biol Chem (1970) 0.79